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Abstract
The androgen receptor (AR) is a ligand-induced transcription factor and contains the polyglutamine (polyQ) tracts within its
N-terminal transactivation domain. The length of polyQ tracts has been suggested to alter AR transcriptional activity in
prostate cancer along with other endocrine and neurologic disorders. Here, we assessed the role of ZMIZ1, an AR co-
activator, in regulating the activity of the AR with different lengths of polyQ tracts as ARQ9, ARQ24, and ARQ35 in prostate
cancer cells. ZMIZ1, but not ZMIZ2 or ARA70, preferably augments ARQ9 induced androgen-dependent transcription on
three different androgen-inducible promoter/reporter vectors. A strong protein-protein interaction between ZMIZ1 and
ARQ9 proteins was shown by immunoprecipitation assays. In the presence of ZMIZ1, the N and C-terminal interaction of the
ARQ9 was more pronounced than ARQ24 and ARQ35. Both Brg1 and BAF57, the components of SWI/SNF complexes, were
shown to be involved in the enhancement of ZMIZ1 on AR activity. Using the chromatin immunoprecipitation assays (ChIP),
we further demonstrated a strong recruitment of ZMIZ1 by ARQ9 on the promoter of the prostate specific antigen (PSA)
gene. These results demonstrate a novel regulatory role of ZMIZ1 in modulating the polyQ tract length of AR in prostate
cancer cells.
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Introduction
Androgen signaling is mainly mediated through the androgen
receptor (AR) and plays a critical role in male sexual development
and in normal and malignant prostatic cell growth and survival
[1]. AR is a member of the steroid hormone receptor superfamily.
Like other steroid hormone receptors, AR contains four functional
domains: an N-terminal transactivation domain (NTD), a central
DNA-binding domain (DBD), a hinge region between the DBD
and LBD domains, and a C-terminal ligand-binding domain
(LBD) [2]. The NTD of human AR is encoded by exon 1,
containing polyglutamine (polyQ) tract. It has been suggested that
this unique sequence structure modulates the activity of AR
mediated transcription. The biological significance of the polyQ
tract abnormality has been explored in human diseases. Expansion
of the polyQ length within the AR NTD directly links to spinal
and bulbar muscular atrophy/Kennedy’s disease (SBMA), a rare,
X-linked, adult onset, neurodegenerative disorder [3,4,5]. Male
patients with this disorder often have symptoms of partial
androgen insensitivity indicative of aberrant AR function, such
as gynecomastia and testicular atrophy [6,7]. The length of the
polyQ repeats within AR has also been implicated in other human
disorders, including the inherited form of androgen insensitivity
(AIS), hereditary hearing impairment, schizophrenia, and benign
prostatic hyperplasia [7,8,9]. Conversely, multiple lines of
evidence have shown that the length of the AR polyQ tract is
inversely correlated with the risk of developing prostate cancer,
age of onset, and risk of advanced disease at diagnosis [10,11,12].
The AR mediated transcription is modulated in a ligand-
dependent manner and facilitated through multiple co-regulators
[13,14]. Similar to other receptors,the unbound AR formsa complex
with heat-shock proteins, HSPs [15]. Upon binding to ligands, the
AR dissociates from the HSPs and translocates into the nucleus,
whereitbindstotheandrogenresponseelement(ARE),recruitsother
transcriptional cofactors, and induces ligand-dependent transcription
[2]. The recruitment of transcriptional co-regulators and the basal
transcriptional machinery is essential for conferring the full
transcriptional activity of AR. An inverse correlation between the
length of the polyQ region and the activity of AR-mediated
transcription has been implicated [16]. It has been shown that
increasing polyQ length negatively affects AR co-activators, p160,
mediated co-activation of the AR [17,18,19]. AR proteins containing
a shortened polyQ length showed stronger interaction with p160 co-
activators and components of the SWI/SNF chromatin-remodeling
complexes than the wild type AR [19]. Ras-related nuclear protein/
ARA24 was identified as an AR co-activator that interacts with the
AR polyQ region [20]. The activity of ARA24 was reduced or
diminished with the polyQ expansion within AR. These data suggest
that the interactions between AR co-regulators and the polyQ region
of AR affect AR-mediated transcription.
ZMIZ1, original named Zimp10 (zinc finger-containing, Miz1,
PIAS-like protein on chromosome 10), has been demonstrated as
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identified between the AR NTD and the central region of ZMIZ1.
Sequence analysis revealed that ZMIZ1shares a highly conserved
SP-RING/Miz domain with members of the PIAS family [22]. In
addition to the SP-RING/Miz domain, ZMIZ1 also contains a
nuclear localization sequence (NLS) and two proline-rich regions
[21]. Importantly, a strong intrinsic transactivation domain was
identified within the C-terminal region of ZMIZ1, through which
ZMIZ1 augments AR-mediated transcription [21]. ZMIZ1 has
also been shown to co-localize with AR and small ubiquitin-like
modifier SUMO-1 and forms a protein complex at replication foci
in the nucleus [21,23]. To further understand the role of ZMIZ1
in regulating AR-mediated transcription, we investigated the role
of ZMIZ1 in modulating the transcriptional activity of AR
containing different lengths of polyQ tract. Intriguingly, ZMIZ1
showed stronger enhancement of ligand-induced transcription
with the AR proteins possessing the short polyQ tracts. Using
different biochemical and functional approaches, we further
assessed the effect of ZMIZ1 in the interaction between the N-
and C-terminuses of AR and the potential mechanisms underlying
ZMIZ1 in modulating AR-mediated transcription.
Materials and Methods
DNA plasmids
The human AR plasmid, pSV-hAR, was kindly provided by Dr
Albert Brinkmann (Erasmus University, Rotterdam, The Nether-
lands). The AR plasmids containing different polyQ tracts were
generously supplied by Dr. Gerhard A. Coetzee (USC, Los Angles,
California). The DNA fragments of the AR NTD with different
polyQ tracts, LBD, and DBD were generated by PCR approaches
with appropriate primers and then subcloned in-frame into either
the pGEX4T1 vector for producing GST fusion proteins, or
pcDNA3.1, pSV, and pLentiSuper expression vectors [24]. The
human Brg1 and BAF57 expression vectors were gifts from Dr.
Gerald Crabtree (Stanford University) and the expression vector
for ARA70 and the pARE-luc reporter were kindly provided by
Dr. Chawnshang Chang [25]. pcDNA3-FLAG-ZMIZ1, pcDNA3-
FLAG-ZMIZ2, and pcDNA3-FLAG-ARA70 were made in the
lab as described previously [21,26]. The pPSA7kb-luc was kindly
provided by Dr. Jan Trapman [27]. MMTV-luc was kindly
provided Dr. Richard Pestell [28]. pSV-b-galactosidase (b-gal)
reporter plasmid (Promega, Madison, WI), was used in this study
as an internal control.
Cell cultures, transfections, lentivirus production, and
reporter assays
DU145 and PC3, human prostate cancer cell lines from the
American Tissue Culture Collection (ATCC, HTB-81 and CRL-
1435), CV-1, a monkey kidney cell line [29], and SW13, a human
adrenal carcinoma cell line [30], were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 5 or 10%
fetal bovine serum (HyClone, Denver, CO). Lentiviruses were
generated by cotransfection of pLenti-puro-ARQ9, pLenti-puro-
ARQ24, or pLenti-puro-ARQ35, with pCMV-dR8.91 and
pMD2.G-VSVG into HKE293 cells at a ratio of 3:2:1 using a
LipofectAMINE2000 kit (Invitrogen) as described previously
[31,32]. The media were replaced at 6 hr post transfection and
then collected 36–40 hr later. The viral supernatant was
centrifuged briefly to remove cellular debris and stored at
280uC. Lentivirus infection was carried out in the presence of
6 mg/ml polybrene, and then selected with puromycin (Sigma)
after 48 hrs. DU145 cells with stable expression of different AR
polyQ length proteins were selected and tested for the expression
of AR proteins.
Transient transfections were carried out using a Lipofectamine
2000 transfection kit (Invitrogen, Carlsbad, CA). Approximately
1.5–2610
4 cells were plated in a 48-well plate 16 hr before
transfection. Approximately 200 ng of total plasmid DNA was
used per well. The total amount of plasmid per well was kept
constant by adding empty pcDNA3 or pBluescript vectors
(Stratagene, CA) as needed. Individual transfection experiments
were repeated a minimum of three times in triplicate with at least
two different preparations of plasmid DNA. Approximately 12–
16 hr after transfection, the cells were fed medium containing 5%
charcoal-stripped fetal calf serum (FCS, HyClone, Denver, CO) in
the presence or absence of dihydrotestosterone (DHT). Whole cell
lysates were prepared and used for luciferase and b-gal assays as
described previously [33]. Luciferase activity is measured after a
5 sec delay following injection of 50 ml luciferase buffer and 50 ml
luciferin into 50 ml cell lysate by the dual injector luminometer,
according to manufacturer’s instruction (Analytical Luminesence
Lab., San Diego, CA). The relative luciferase unit (RLU) from
individual transfections was normalized by measurement of b-
galactosidase (luciferase/b-galactosidase) activity expressed from a
cotransfected plasmid in the same samples. RLUs were deter-
mined from three independent transfection experimetns and are
presented as the mean 6 SEM of the triplicate transfections.
Immunoprecipitation and Western Blotting
DU145 cells infected with pLenti-puro-ARQ9, ARQ24, or
ARQ35 were subsequently transfected with the FLAG-tagged
hZMIZ1 expression vectors. Transfected cells were cultured in the
presence of 10 nM DHT for 48 h and then harvested in a buffer
containing 0.5% Nonidet P-40, 150 mM NaCl, 2 mM MgCl2,
50 mM HEPES-KOH (pH 7.4), 1 mM EDTA, 5% glycerol,
1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride,
25 mM NaF. Lysates were clarified by incubation on ice and
centrifugation for 5 min. Four hundred ml of clarified lysate from
each sample was precleared for 20 min with 10 ml of protein-A
sepharose beads bound to 1 mg of normal mouse IgG (Pharmacia).
Precleared lysates were then incubated with pre-equilibrated
protein-A-Sepharose beads with either normal rabbit IgG or AR
polyclonal antibody (Cat#: 06-680, Upstate Biotechnology, NY)
at 4uC for 3 h. The beads were collected by centrifugation, and
gently washed 3 times with the same buffer as described above.
Proteins were eluted by boiling in SDS-sample buffer and resolved
on a 10% SDS-PAGE, and transferred onto a nitrocellulose
membrane. Membranes were probed with AR (sc-816, Santa Cruz
Biotechnology) or FLAG (F3165, Sigma) antibody at 1:500 or
1:1000 dilutions, respectively. Anti-rabbit or mouse IgG conju-
gated to horseradish peroxidase was used as secondary antibodies
at the dilution 1:1000 (Cat#170-6515 or Cat#170-6516, Bio-
Rad, Hercules, CA). Detection was performed with ECL reagents
according to the manufacturer’s protocol using ECL Hyperfilm
(Amersham Biosciences).
GST Pull down Assay
Glutathione S-transferase (GST) fusion proteins with the AR
NTD domain of polyQ-ARQ9, Q24, Q35, the full length of
ZMIZ1, and ARA70 were constructed in the pGEX-2TK vector
(Amersham, Arlington Heights, IL). Expression and purification of
GST fusion proteins were performed as described previously [33].
Equal amounts of GST fusion proteins coupled to glutathione-
Sepharose beads were incubated with the radio-labeled proteins or
whole cell lysates at 4uC for 4 h in a modified binding buffer
(20 mM Tris-HCl, pH 7.8, 180 mM KCl, 0.5 mM EDTA, 5 mM
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dry nonfat milk, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfo-
nyl fluoride) in the presence of 10 nM DHT. Beads were carefully
washed 3 times with 500 ml of binding buffer and then analyzed by
SDS-PAGE followed by autoradiography or immunoblotting with
appropriate antibodies.
Chromatin immunoprecipitation (ChIP) Assays
DU145 cells stably transfected with 7 Kb-PSA promoter
plasmids were infected with different AR polyQ lentiviral vectors,
and then subsequently transfected with FLAG-tagged hZMIZ1
expression vectors. Cells were selected with puromycin and G418
for at least 7 day. For ChIP assays, cells were replated and cultured
in the medium containing 5% charcoal-stripped FCS in the
presence or absence of 10 nM DHT at 37uC for 12 hours, and
then washed with PBS. After the last wash with PBS, cells were
treated with formaldehyde [34]. Cells were then collected and
washed sequentially with cold PBS, Wash Buffer I (0.25% Triton
X100, 10 mM EDTA, 0.5 mM EGTA and 10 mM HEPES,
pH 6.5), and Wash Buffer II (200 mM NaCl, 1 mM EDTA,
0.5 mM EGTA and 10 mM HEPES, pH 6.5). Cells were lysed in
buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1, and
protease inhibitors). The chromatin was sheared to an average size
of 800 bp by sonication and diluted ten-fold in ChIP dilution
buffer (2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1,
1% Triton X-100), and then subjected to immunoprecipitation
with an anti-AR antibody (Cat# 06-680, Upstate), anti-FLAG
antibody (Cat#F3165, Sigma), or normal IgG for overnight at
4uC and recovered with Protein A Sepharose (Amersham). The
immuno-complexes were eluted from the beads through incuba-
tion with 106 bead volume of elution buffer (1% SDS, 0.1 M
NaHCO3). Crosslinks were reversed by incubating elution samples
at 65uC for 6 hrs and chromatin fragments were purified with the
PCR Purification Kit (Qiagen). ChIP and input DNA were
analyzed by PCR using PSA promoter-specific primers reported
previously [35]. AREI-forward: TCTGCCTTTGTCCCCTA-
GAT, reverse: AACCTTCATTCCCCAGGACT; AREII for-
ward: AGGGATCAGGGAGTCTCACA, reverse: GCTAG-
CACTTGCTGTTCTGC; AREIII forward: CTGCTCAGCCT-
TTGTCTCTG, reverse: CAGATCCAGGCTTGCTTAC. Sam-
ples were also amplified with E/F primers for controls: forward:
CTGTGCTTGGAGTTTACCTGA, and reverse: GCA-
GAGGTTGCAGTGAGCC.
Results
ZMIZ1 enhances the transcriptional activity of AR with
shorter polyQ tract
Full activity of the ligand-induced AR mediated transcription is
facilitated through the interactions between the AR and its co-
regulators [13,14]. Previous studies have shown that the length of
AR polyQ repeats influences the transcriptional activity of AR
[19,36]. ZMIZ1 is an AR co-activator and interacts with the NTD
of AR. In this study, we assessed the possible effect of ZMIZ1 on
the transactivity of AR with different polyQ tracts. Expression
vectors for the human AR cDNA containing 9, 24, and 35 polyQ
tracts and for AR cofactors, including ZMIZ1, ZMIZ2, and
ARA70, were co-transfected with an androgen-induced luciferase
reporter driven by a 7 Kb PSA promoter-enhancer fragment into
prostate cancer cell line, DU145. A ligand-induced transactivation
on the PSA luciferase reporter was observed in all of the samples
transfected with different AR polyQ length expression vectors
whereas the samples transfected with ARQ9 showed the highest
induction (Fig. 1). There is no significant change in expression of
the above exogenous proteins in each sample (please see Fig. S1).
Co-expression of ZMIZ1 with different AR polyQ vectors further
increased the ligand-induced activity. Particularly, ZMIZ1 showed
a significant enhancement on ARQ9 and Q24 mediated
transcription in a dosage dependent manner but not on ARQ35
(Fig. 1A, 1B). ARA70, an AR co-activator, also showed
Figure 1. ZMIZ1 selectively enhances the shorter polyQ-AR mediated transcription. DU145 cells were transiently transfected in 48-well
plates with 100 ng of 7 kb PSA-Luc, 25 ng of pSV40-b-gal, 5 ng of ARQ9, Q24, or Q35, and 10 or 30 ng of pcDNA3-FLAG-hZMIZ1, pcDNA3-FLAG-
hZMIZ2, or pcDNA3-FLAG-ARA70 as where are indicated. The total amount of plasmids per well was normalized in all transfections by the addition of
pcDNA3 empty vector. Twenty-four hours after transfection, cells were incubated with or without 1 nM DHT for another 24 hours and then whole cell
lysates were prepared for assessment of luciferase and b-gal activities. Transfection experiments were repeated a minimum of three times in
triplicate. Relative luciferase units (RLUs) were determined from three independent transfections and are presented as the mean 6 SEM of the
triplicate transfections. ‘‘*’’ indicates a statistically significant difference (p,0.05) between the samples co-expressed AR and other AR co-factors in the
presence of 1 nM DHT.
doi:10.1371/journal.pone.0025040.g001
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with 100 ng of 7 kb PSA-Luc, 25 ng of pSV40-b gal, 5 ng of ARQ9, Q24, or Q35, and where indicated, with 10 ng of pcDNA3 empty vector or pcDNA3-
FLAG-hZMIZ1. Twenty-four hours after transfection, cells were incubated in the absence of DHT or in the presence of 0.1, 1, or 10 nM of DHT for 24 h.
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appeared in the samples in the presence and absence of DHT.
There was little or no effect in the samples transfected with
ZMIZ2, a homolog of ZMIZ1. We repeated the above transient
transfection experiments in PC3, a human prostate cancer cell
line, and CV-1 cells, a monkey kidney cell line, and observed the
similar results (data not shown). Overall, this was first line of
evidence that ZMIZ1, rather than ZMIZ2 or ARA70, enhances
the ligand-induced transactivation of AR with shorter polyQ tract
in prostate cancer cells.
ZMIZ1 enhances transactivation of the shorter polyQ AR
at physiologic androgen concentration
To explore the biological relevance of ZMIZ1 on the AR with
different polyQ tracts, we expanded our investigation by assessing
the effect of ZMIZ1 on different AR polyQ proteins at various
ligand concentrations and different androgen-induced promoters/
reporters in DU145 cells. Three different androgen-inducible
reporters were tested in the experiments, including the 7 kb PSA
promoter (PSA-luc), a mouse mammary tumor virus promoter
reporter (MMTV-Luc), and a minimum promoter with three
ARE-luc reporter. ZMIZ1 showed a significant enhancement of
both ARQ9 and Q24 transcriptional activities on the PSA-
promoter/reporter in the presence of 1 and 10 nM DHT (Fig. 2A).
However, in the presence of 0.1 nM DHT, only slight induction
was observed in all of the samples transfected with the three
different AR polyQ proteins. Expression of ZMIZ1 significantly
increased ARQ9 activity on the MMTV- and ARE-promoters/
reporters in the presence of 1 and 10 nM DHT but only affected
ARQ24 in the presence of 10 nM DHT (black bars, Fig. 2B and
2C). Particularly, the samples co-expressed with ZMIZ1 and
ARQ9 in the presence of 10 nM DHT displayed the highest
ligand-induced activity on the MMTV-promoter/reporter. The
above data demonstrated that ZMIZ1 preferably enhances the
activity of AR proteins containing short polyQ lengths on three
different androgen induced promoters in the presence of
physiologic levels of androgens in prostate cancer cells.
Enhancement of shorter polyQ AR mediated
transcription by ZMIZ1 is associated with the
components of SWI/SNF complexes, Brg1 and BAF57
The Drosophila ortholog gene of ZMIZs, tonalli (tna), has been
shown to genetically interact with the SWI/SNF and Mediator
chromatin remodeling complexes [37]. The interactions between
ZMIZ proteins and Brg1and BAF57, the components of SWI/SNF
complexes, have been demonstrated [23,26]. In addition, the SWI/
SNF chromatin-remodeling complexes and p160 co-activators have
been shown to interact strongly with AR proteins containing a
shortened polyQ length in comparison to the wild type AR [19].
Therefore, we nextexamined the involvement of the SWI/SNF-like
BAF complexes in ZMIZ1 regulated AR transcription. A nearly 2,
3, or 5 fold ligand-induced transactivation was observed in the cells
transfectedwith ARQ35,Q24, or Q9 expression vector plasmids on
the PSA luciferase reporter, respectively (Fig. 3A). Whereas co-
transfection of the Brg1 or ZMIZ1 alone with three different ARQ
expression vectors slightly increased the androgen-induced activity
on the PSA luciferase reporter, combined expression of both
proteins showed a significant enhancement on ARQ9 mediated
transcription in a dose dependent manner in comparison to the
samples with ARQ24 or Q35 (Fig. 3A). Using similar approaches,
we further tested the potential effect of BAF57, a Brg1-associated
protein, in ZMIZ1 regulated enhancement of AR polyQ constructs.
As shown in Figure 3B, co-expression of ZMIZ1 with Brg1 alone or
plus BAF57 significantly enhanced ligand induced activity of ARQ9
or ARQ24 on the PSA-luc reporter. These results demonstrated
that Brg1 or BAF57 cooperatively augment ARQ9 mediated
transcription with ZMIZ1.
Next, we further assessed the role of the SWI/SNF-mediated
complexes inZMIZ1regulated AR activityusing the human adrenal
carcinoma cell line, SW13, which is deficient in both BRG1 and Brm
expression and considered to lack functional SWI/SNF complexes
[30]. Overexpression of ARQ9 but not Q24 and Q35 conferred
aboutaonefoldligand-inducedactivityofthePSAreporter(Fig.3C).
Either transfection of Brg1 alone or combined with BAF57 showed
no significant changes in AR activity. However, co-expression of
ZMIZ1 with Brg1 or with Brg1 and BAF57 significantly enhanced
the activity of ARQ9 and ARQ24 on the PSA promoter/reporter.
The data further suggested that the Brg1- and BAF57-regulated AR
activity is mediated through ZMIZ1.
The transactivating effect of ZMIZ1 on shorter polyQ AR
confers resistance to androgen antagonists
The current literature has shown that the expression of AR and
its downstream target genes remain at high levels in castration
resistant prostate cancer [14,38]. A promotional role of AR co-
regulators in prostate cancer progression has also been suggested
[39,40]. Here, we examined the effect of ZMIZ1 on different AR
polyQ vectors in the presence of antagonists in the prostate cancer
cell line, DU145. In the presence of 1 nM DHT, overexpression of
ARQ9 and Q24 produced nearly 3 to 2 fold ligand-induced
activity on the PSA reporter, respectively (Fig. 4). Approximately
60% and 30% enhancement was generated in the cells co-
transfected with ZMIZ1 and ARQ9 or ARQ24 expression vectors.
Addition of 100 nM of two anti-androgens, bicalutamide or
flutamide, reduced transcriptional activity in DU145 cells
transfected with ARQ24 or ARQ35 alone or co-transfected with
ZMIZ1. On the contrary, anti-androgens showed less repressive
effect on the cells transfected with ARQ9 alone or plus ZMIZ1.
Particularly, DU145 cells co-expressed with ARQ9 and ZMIZ1
proteins demonstrated significant resistance to inhibition by
antiandrogens in comparison to cells co-expressed ARQ24 and
Q35 proteins. We repeated these experiments on PC3 and CV1
cells and observed similar results (data not shown). These data
suggest a role for ZMIZ1 mediated enhancement of shorter polyQ
AR to escape anti-androgen blockade in prostate cancer cells.
ZMIZ1 interacts with AR polyQ proteins
To search for the potential mechanisms by which ZMIZ1
enhances shorter polyQ AR mediated transcription, we carried out
co-immunoprecipitation assays to examine the interaction between
ZMIZ1 and different AR polyQ proteins. We expressed FLAG-
tagged ZMIZ1 together with different AR polyQ proteins in
DU145 cells. Whole cell lysates containing almost equal amounts of
Cell lysates were prepared for assessment of luciferase and b-gal activities. The transfection experiments were repeated three times in triplicate.
Relative luciferase units (RLUs) were determined from three independent transfections and are presented as the mean 6 SEM of the triplicate
transfections. ‘‘*’’ indicates a significant difference (p,0.05) between the samples co-expressed with different AR polyQ and ZMIZ1 proteins in the
presence of different concentration of DHT, (B) Similar to (A), except that a MMTV-luc reporter (100 ng) was used. (C) Similar to (A), except that an
ARE-luc reporter (100 ng) was used.
doi:10.1371/journal.pone.0025040.g002
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anti-AR antibody (Fig. 5A). As shown in Fig. 5B, similar levels of
ARQ9, Q24, and Q35 were shown in the anti-AR antibody bound
immunoprecipitates, which migrated differently in SDS-PAGE gels
due to the length of polyQ tracts. Intriguingly, the FLAG-tagged
ZMIZ1 protein band appeared more intense in the immunopre-
cipitate sample with ARQ9 expression than samples with ARQ24
or Q35. To confirm our finding, we performed reverse immuno-
precipitation experiments with the FLAGantibody. Whereas nearly
equal amounts of FLAG-ZMIZ1 proteins were detected in all of
samples with a ZMIZ1 antibody, the ARQ9 showed stronger
staining with the AR antibody than ARQ24 or ARQ35 proteins.
Taken together, the above data indicate that ZMIZ1 interacts more
strongly with the shorter polyQ AR in prostate cancer cells.
ZMIZ1 affects the interactions between NH2- and
carboxyl terminus of AR
It has been shown that the intramolecular interaction between
the AR NTD and LBD is essential for forming a composite
binding site to recruit transcriptional co-regulators to confer the
full transcriptional activity [41]. The short polyQ length can
enhance the ligand-induced N to C-terminal intramolecular
interaction [19]. Therefore, we assessed the potential role of
ZMIZ1 on the N/C interaction of AR with different polyQ tracts.
We first examined the interactions between the NTDs with
different polyQ repeats and the AR DBD or LBD using GST pull-
down assays. The GST fusion proteins containing the AR DBD
and LBD were generated (Fig. 6B), and incubated with equal
amounts of the truncated NTDs with different polyQ tracts
generated in vitro using the TNT-coupled reticulocyte lysate
systems (Fig. 6A). The protein-protein interactions were analyzed
by SDS-PAGE and autoradiography (Fig. 6C). Specific retentions
of the AR NTDs were observed in the samples incubated with
GST-AR LBD protein as well as ARA70, used as a control. Both
ARQ9 and ARQ24 showed a strong interaction with the AR LBD
in comparison to ARQ35, which is consistent with the previous
report [19]. Next, we analyzed the effect of ZMIZ1 on the AR N/
C terminal interactions. The GST-AR LBD showed a specific
Figure 3. The enhancement of ZMIZ1 on shorter polyQ-AR mediated transcription is associated with SWI/SNF complex, Brg1 and
BAF57. (A) DU145 cells were transfected with a luciferase reporter driven by the human PSA promoter (100 ng), pcDNA3-b-gal (25 ng), 5 ng of
ARQ9, Q24, or Q35, and where indicated, with 15 ng of pcDNA3 empty vector or pcDNA3-FLAG-ZMIZ1, different amounts of pcDNA3-Brg1 as
indicated. Cells were incubated 24 h after transfection in the presence of 10 nM DHT for 24 h. The transfection experiments were repeated three
times in triplicate. Relative luciferase units (RLUs) were determined from three independent transfections and are presented as the mean 6 SEM of
the triplicate transfections. Statistical analyses showed significant differences (p,0.05) between the samples expressed different AR Q proteins only
or co-expressed AR and other co-factors in the presence of DHT, ‘‘*’’. (B) DU145 cells were transfected with a luciferase reporter driven by the human
PSA promoter (100 ng), pcDNA3-b-gal (25 ng), 5 ng of ARQ9, Q24, or Q35, and where indicated, with 10 ng of pcDNA3 empty vector or pcDNA3-
FLAG-ZMIZ1, or different amounts of pcDNA3-Brg1 or pcDNA3-BAF57 as indicated. Cells were incubated 24 h after transfection in the presence of
10 nM DHT for 24 hr. Cell lysates were then prepared for assessment of luciferase and b-gal activities. Data were analyzed as described in (A). (C)
Similar to (A), except in SW-13 cells.
doi:10.1371/journal.pone.0025040.g003
Figure 4. The effect of ZMIZ1 on shorter poly-Q AR is insensitive to androgen antagonist. DU145 cells were transfected with a luciferase
reporter driven by the human PSA promoter (100 ng), pcDNA3-b-gal (25 ng), 5 ng of ARQ9, Q24, or Q35, and where indicated, with 10 ng of pcDNA3
empty vector or pcDNA3-FLAG-ZMIZ1. Twenty-four hours after transfection, cells were incubated with different androgen antagonist, including
100 nM of Bicalutamide or Flutamide for 24 h. Cell lysates were prepared for luciferase and b-gal assays. The transfection experiments were repeated
three times in triplicate. Relative luciferase units (RLUs) were determined from three independent transfections and are presented as the mean 6 SEM
of the triplicate transfections. Statistical analyses showed significant differences (p,0.05) between the samples co-expressed with different AR polyQ
and ZMIZ1 proteins in the presence of anti-androgens, ‘‘*’’.
doi:10.1371/journal.pone.0025040.g004
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of ZMIZ1, the interactions between the AR LBD and the NTDs of
ARQ9 and ARQ24 were increased in comparison to ARQ35.
However, there was only slight change between the samples co-
expressed with ARA70 and AR polyQ proteins (Fig. 6E).
Measurements of binding by densitometry showed enhancement
of N/C interaction in ARQ9 and ARQ24 by ZMIZ1 (Fig. 6F).
Next, we performed chromatin immunoprecipitation (ChIP)
assays to evaluate the effect of ZMIZ1 on AR-occupied promoters.
DU145 cells stably transfected with 7 kb-PSA promoter-luciferase
reporter plasmids as well as different AR polyQ with or without
ZMIZ1 expression vector were used in the experiments. Almost
equal levels of exogenous AR and ZMIZ1 proteins were observed
by Western blotting in each subline with expression of different
AR polyQ protein (Figure S2A). Soluble chromatin was isolated
from the formaldehyde treated DU145 cells, sheared by
sonication, and immunoprecipitated by anti-AR antibodies or
normal IgG as controls. The genomic DNA samples were isolated
and then analyzed by PCR using specific pairs of primers spanning
the AR-binding sites in the PSA promoter (Figure 7A). We first
assessed a specific recruitment of AR on the AREI element using
the primer pair labeled as A/B. As shown in Figure 7B, the PCR
fragments containing ARE1 were only detected in the immuno-
precipitates bound with the AR antibody but not in the controls
with normal IgG. PCR fragments showed an increase in the
ARQ9 expressed cells in comparison to ones with ARQ24 and
ARQ35 (Fig. 7B). Using similar approaches, we then evaluated the
effect of ZMIZ1 on the recruitment of different AR polyQ proteins
on three ARE sites within the PSA promoter region (Fig. 7A). The
intensities of PCR fragments containing AREI, AREII, and
AREIII were similar or slightly increased in samples co-expressed
with ARQ9 in comparison to samples with ARQ24 and ARQ35.
However, in the presence of ZMIZ1, a marked increase in the
AREI and AREIII PCR fragments was observed in the DHT-
induced ARQ9 expressed cells (Fig. 7C). We confirmed these
findings by reciprocally immunoprecipitating ZMIZ1 using the
same soluble chromatin samples. A significant increase of AREI
and AREIII binding was observed in samples co-expressed with
ARQ9 and ZMIZ1 in comparison to ARQ24 or ARQ35 and
ZMIZ1 (Figure S2B). We also performed qPCR to quantitate the
bindings using the AR antibody bound DNA and input DNA
samples as templates (Figure S3). A significant increase of ARQ9
binding to AREI and AREIII sites was observed in the samples co-
expressing ZMIZ1 in comparison to other samples. These data
demonstrated that ZMIZ1 selectively enhances the recruitment of
shorter polyQ AR onto the PSA promoter, resulting in stronger
binding to AREI and AREIII sites.
Discussion
The importance of the androgen receptor has been implicated
in both normal prostate development and prostate cancer
pathogenesis. The AR mediates most of its action through
regulation of transcription of its downstream target genes. Unlike
other nuclear hormone receptors, the AR contains a relatively
weak activation function 2 (AF2) domain within the ligand-binding
domain (LBD). The NTD is coded by exon 1 and does not share
homologies with other steroid receptor family members [2]. The
NTD contains two transactivation regions. The main transactiva-
tion region (AF-1) in the NTD spans between amino acids 51 and
211, which encompasses the polyQ tract. Very similar polyQ
tracts have been identified in other transcription factors such as the
TATA box binding protein (TBP) [42]. Previous studies have
suggested that the polymorphic polyQ tract of the AR NTD might
be involved in the control of AR mediated transcription by
facilitating protein–protein interactions with other transcriptional
factors [17,19,20]. Previously, we demonstrated that ZMIZ1 is an
AR interacting protein. ZMIZ1 binds primarily to the region
between amino acids 243–333, which is between two AF regions
within the NTD [21]. In this study, we showed that ZMIZ1 binds
to the AR polyQ9 proteins much stronger than AR polyQ24 and
polyQ35 in the immunoprecipitation assays. We also observed a
pronounced effect of ZMIZ1 in enhancing the N- and C- terminal
interaction of AR with short polyQ tracts. It has been suggested
that the intramolecular interaction between the AR NTD and
LBD is essential for forming a composite binding site to recruit
transcriptional co-regulators to confer the full transcriptional
activity [19,41]. Therefore, our findings suggest that ZMIZ1
facilitates a strong interaction between the N- and C-terminus of
short polyQ AR that leads to recruitment of other transcriptional
co-regulators and activate transcription.
Previously, we demonstrated that both ZMIZ1 and ZMIZ2
interact with AR and enhance AR mediated transcription [23].
These two proteins share significant sequence similarity, particu-
larly within their C-terminal regions [26]. They contain an
intrinsic transactivation domain and function as transcriptional co-
activators [21,26]. These two ZMIZ proteins show different tissue
distribution profiles, suggesting distinct roles for these proteins in
Figure 5. ZMIZ1 preferably binds to the AR protein with a short
polyglutamine tract. (A) DU145 cells stably expressing different
polyQ AR proteins were transfected with pcDNA3-FLAG-ZMIZ1. Cell
lysates were harvested and then immunoprecipitated with anti-FLAG
antibody or normal mouse IgG. 5% input of the cell lysates was probed
with the anti-FLAG, AR, or Tublin antibody. (B) Immunoprecipitates
pulldowned by the AR antibody or normal IgG (IP) were analyzed by
Western bolt and probed by AR and FLAG antibodies. (C) Immunopre-
cipitates pulldowned by the FLAG antibody and IgG (IP) were analyzed
by Western blot and probed by ZMIZ1 or AR antibody.
doi:10.1371/journal.pone.0025040.g005
ZMIZ1 Enhances the Activity of the Short PolyQ AR
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25040regulating the expression of different target genes. In this study, we
observed a remarkable enhancement of ARQ9 mediated tran-
scription by ZMIZ1 and not ZMIZ2. These observations further
suggested that ZMIZ1 and ZMIZ2 proteins, although structurally
similar, likely play different roles in modulating transcription. In
addition, ARA70, another AR associated protein, did not show a
significant effect on ligand-induced transcription of different
polyQ length AR proteins. These observations further implicate
that the enhancement by ZMIZ1 on short polyQ AR proteins is a
specific effect and needs to be further evaluated.
A homologue of ZMIZ1 and ZMIZ2, termed tonalli (tna) was
identified previously in Drosophila [37]. The protein encoded by tna
was shown to interact with SWI2/SNF2 and the Mediator
complex, suggesting a potential role for the ZMIZ proteins in
chromatin modification. Previously, we demonstrated that the
ZMIZ proteins interact with both Brg1 and BAF57, DNA-binding
subunits of the mammalian SWI/SNF-like BAF complexes that
enhance AR mediated transcription [43]. It has been shown that
BAF57 can directly bind to the AR and be recruited to the
endogenous AR target promoter upon ligand activation [44,45].
Therefore, we assessed the involvement of Brg1 and BAF57 in
ZMIZ1 mediated enhancement of AR activation. Using SW13
cells, which were deficient in both BRG1 and Brm expression and
considered to lack the functional SWI/SNF complexes [30], we
demonstrated the requirement of both Brg1 and BAF57 in the
enhancement of ZMIZ1 on ARQ9 mediated transcription. The
observation provides additional evidence that the mammalian
SWI/SNF-like BAF complexes play a role in ZMIZ1-mediated
AR activation.
Different mutations in the AR gene have been identified in
various human disorders, including endocrine dysfunctions and
prostate cancer. Most loss-of-function mutations in the AR gene
result in the inactivation of AR function through impairing the
androgen-dependent transcription [8]. Particularly, extended
lengths of polyQ repeats within the AR NTD can result in
dysfunctional AR and have been identified in patients with
androgen insensitivity syndrome, (AIS). In contrast, gain-of-
function mutations have been identified in prostate cancers and
hirsutism in females [6,7,46]. While the molecular mechanisms
underlying these mutations in the pathogenesis of the above
human disorders are unclear, the inverse correlation between the
length of polyQ tracts and the transcriptional activity of AR has
been observed in prostate cancer patients [3,5,12]. In this study,
we confirmed the previous observations that the AR containing
the shorter length of polyQ tracts has the higher transcriptional
activity on three different androgen-inducible promoter/reporter
constructs. Most importantly, we observed much stronger
enhancement by ZMIZ1 on ARQ9 mediated transcription in
comparison to ARQ24 or ARQ35. ZMIZ1 contains a very strong
intrinsic transcriptional domain in the C-terminal proline rich
domain. Through specific protein-protein interaction, ZMIZ1 can
be recruited into the AR-involved transcriptionally active
complexes to facilitate AR mediated transcription. We used
chromatin immunoprecipitation assays (ChIP) to demonstrate a
specific recruitment of ZMIZ1 on the androgen response elements
with the PSA promoter region. Since the full transcriptional
activity of AR is conferred through other co-activators, the above
data suggest a potential mechanism underlying the short length of
Figure 6. ZMIZ1 enhances the interaction between the N- and
C- terminuses of AR. (A) Equal amounts of in vitro translated
35S
methionine-labeled NTD domain of ARQ9, Q24, Q35 or ARA70 were
measured and used in GST pull down assays. (B) GST-AR LBD (amino
acids: 676–919), GST-AR DBD (aa: 559–624), or GST protein alone, as a
negative control, were isolated, purified, and subjected to binding
assays. Equal amounts of the above GST proteins were analyzed on
SDS-PAGE. (C) Equal amounts of the in vitro translated NTD of ARQ9,
Q24, Q35 or ARA70 were incubated with different GST fusion proteins
coupled to glutathione-Sepharose beads in the binding buffer (see the
‘‘Material and Methods) with 10 nM DHT for 4 hours at 4uC. The beads
were washed and subjected to SDS-PAGE and autoradiography. (D)
DU145 cells with stable expression of different AR polyQ proteins were
transfected with pcDNA3-FLAG-ZMIZ1, pcDNA3-FLAG-ZMIZ2FLAG, or
pcDNA3 plasmids. Whole cell lysates were prepared from the above
cells and subjected to GST pulldown experiments. Forty ml of GST-AR
LBD beads were mixed with 200 ml of whole cell lysates isolated from
the above DU145 cells and incubated with the binding buffer (see the
‘‘Material and Methods) with 10 nM DHT for 4 hours at 4uC. The GST
beads were washed, eluted, and subjected to SDS-PAGE and
immunoblotting with an anti-AR antibody (sc-7305; Santa Cruz
Biotechnology, Santa Cruz, CA). (E) Ten ml of the above cell lysates
after mixed with GST-AR LBD were analyzed by Western blotting to
assess levels of input from different AR polyQ, FLAG-ZMIZ1 and ARA70
proteins with anti-AR C-terminus (sc-815, Santa Cruz Biotechnology),
anti-AR N-terminus (sc-816, Santa Cruz), or anti-FLAG (cat#3165, Sigma)
antibody, respectively. (F) Densitometry of the membrane bands was
performed, and the relative numbers were reported, as the density of
the binding of AR NTD (D) normalized by the input of AR NTD proteins
(the second top panel, E).
doi:10.1371/journal.pone.0025040.g006
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tion. Therefore, it would be interesting to characterize the
expression of ZMIZ1 and different length polyQ AR in patient
samples of prostate cancer, AIS, and other human disorders that
may be closely related to either loss or gain-of-function mutations
in the AR gene.
In this study, we demonstrated on all three androgen-induced
promoters that ZMIZ1 showed maximal induction on ARQ9
mediated transcription at either 1 or 10 nM of DHT, most close to
the physiological level in humans. These observations suggest the
enhancement by ZMIZ1 on the short polyQ AR activity
represents a biologically relevant event. The humanized AR
mouse lines with different lengths of polyQ tracts have been
generated using germline gene targeting [47]. An inverse
correlation of polyQ tract length with AR transcriptional activity
on its target genes, such as probasin and Nkx3.1, was observed in
the mouse prostate tissues. It would be interesting to investigate the
role of ZMIZ1 on AR with different polyQ tracts using the
relevant mouse models. Intriguingly, our transient transfection
experiments showed that the enhancement by ZMIZ1 on ARQ9
was not inhibited by anti-androgens at 100 nM. Previous studies
have shown that these antiandrogens effectively decrease AR-
mediated transcription at this concentration using the similar
transient transfection assays [48]. Our findings raise an interesting
question regarding the potential significance of ZMIZ1 effects on
AR mediated transcription in prostate cancer pathogenesis and
particularly in disease progression during androgen deprivation
therapy. Further studies into the molecular mechanisms by which
ZMIZ1 regulates AR mediated transcription may provide new
insight into the biological role of ZMIZ1 in prostate cancer and
related human disorders.
Supporting Information
Figure S1 Whole cell lysates were isolated from human
prostate cancer cells, DU145, which were transiently
transfected with 100 ng of 7 kb PSA-Luc, 25 ng of pSV40-
b-gal, 5 ng of ARQ9, Q24, or Q35, and 10 or 30 ng of
pcDNA3-FLAG-hZMIZ1, pcDNA3-FLAG-hZMIZ2, or
pcDNA3-FLAG-ARA70 in the presence 10 nM DHT (see
Figure 1). Western blotting was performed to assess the
expression of AR and other co-activators. Twenty ml of whole
cell lysates were eluted on a 10% SDS-PAGE, and transferred
onto a nitrocellulose membrane. Membranes were probed with
antibodies against AR, FLAG, or b-tublin at the appropriate
dilutions. Anti-rabbit or mouse IgG conjugated to horseradish
peroxidase was used as secondary antibodies (Bio-Red). Detection
was performed with ECL reagents according to the manufacturer’s
protocol using ECL Hyperfilm (Amersham Biosciences).
(TIF)
Figure S2 DU145 cells stably transfected with 7 Kb-PSA-
promoter plasmids and expressed different AR polyQ
proteins were transfected with pcDNA3-FLAG-ZMIZ1
for ChIP analyses. Whole cell lysates were prepared and 10 ml
was used to assess levels of AR and ZMIZ1 proteins by Western
blotting. Almost equal amounts of AR and ZMIZ1 as well as b-
tublin, used as a control, were detected in the different cell samples
(A). Soluble chromatin was isolated from the above cells and
subjected to ChIP assays. FLAG antibodies (Cat#F3165 Sigma)
were used to immunoprecipitate FLAG-ZMIZ1-bound DNA
fragments. Four pairs of primers (see Figure 7A) were used to
amplify the regions containing the ARE sites (B).
(TIF)
Figure S3 DNA templates isolated by immunoprecipi-
tating chromatin by the AR antibody (see the Materials
and Methods and Figure 7) and input DNA samples were
analyzed using Q-PCR with specific primers. The location
of primers within the PSA promoter are indicated in Figure 7A.
Amplification was performed using 12.5 ml of SYBR qPCR Super
Mix Universal (Invitrogen), 10 mM of each primer and 100 ng of
DNA in a final volume of 25 ml in the MX 3005P thermocycler
Figure 7. ZMIZ1 enhances shorter polyQ-AR binding to PSA promoter. (A) Schematic diagram of the human PSA promoter region. Four
pairs of PCR primers marked as A/B, C/D, E/F, and G/H are used to amplify specific AREs. (B) DU145 cells stably transfected with 7 Kb-PSA-promoter
plasmids and expressing different polyQ AR were transfected with pcDNA3-FLAG-ZMIZ1 and incubated in the presence or absence of 10 nM DHT.
Soluble chromatin was prepared from formaldehyde-cross-linked and sonicated cell cultures. Specific antibodies against AR (Cat# Sigma) or normal
IgG as controls were used to immunoprecipitate protein-bound DNA fragments. These fragments were amplified by PCR using primers A and B. (C)
The above soluble chromatin was systemically analyzed by PCR with four pairs of primers as indicated in the figure.
doi:10.1371/journal.pone.0025040.g007
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ation at 95uC for 10 min, followed by 30 cycles at 95uC for 15 s,
55uC for 30 s, and 72uC for 30 s. Serial dilutions of control DNA
ranging from 200 to 0.02 ng were used for quantification of the
signal. The levels of amplification with different primers for AREI
(A), AREII (B), and AREIII (C) were expressed as the fold change
of the input chromatin fraction defined by the following equation:
immunoprecipitated chromatin fraction with AR antibody/input
chromatin fraction. The PCR reactions were repeated three times
in triplicate. The fold changes were determined from three
independent transfections and are presented as the mean 6 SEM.
‘‘*’’ indicates significant differences (p,0.05) between samples co-
expressing different AR Q proteins and ZMIZ1.
(TIF)
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